← All stories
Markets
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.
Covered by 1 outlet
All coverage · 1 article